Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 31
Posts 5,123
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
U.S. Stocks Rise, Staged For Weekly Gain
U.S. stocks shook off a rocky start to extend modest gains on Friday. Stocks are on track for a strong overall week, as investors digest positive economic data and a series of upbeat quarterly results.
Top Equities Stories Of The Day
European Markets Show Signs of Stress--2nd Update
Microsoft Gains Help Lead Tech's Advance
Treasury Bonds Pull Back for Second Straight Day
Will Free Data Become the Next Free Shipping?
Microsoft Braces for Another Nokia Hit--Earnings Preview
Stifel Financial to Hire Two Former Merrill Lynch Advisers
Procter & Gamble Looking at Margins, Brands--Earnings Preview
Pfizer Authorizes $11 Billion Stock Repurchase
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 183172 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist